Eli Lilly just reported the biggest quarter in its 149-year history, beat earnings by more than two dollars a share, and raised its full-year outlook — powered by the same weight-loss and diabetes franchise that made it the world’s most valuable healthcare company.
When the largest drugmaker on the planet grows revenue nearly 50% in a single quarter, it is worth paying attention. On its Q2 2026 report, $LLY posted about $23 billion in revenue, beat on earnings by roughly $2.37 a share, and lifted its full-year revenue guidance — and the stock climbed about 6% toward fresh highs. The engine, again, was tirzepatide: Mounjaro for type 2 diabetes and Zepbound for weight management. The results were detailed in the company’s Q2 2026 release and covered by CNBC.
Eli Lilly is a Dow component, an Indianapolis institution founded in 1876, and — as of late 2025 — the first healthcare company ever to cross a $1 trillion market value. This profile breaks down what Lilly reported, why the raised guidance matters, how the business actually makes money, and the honest risks behind a richly valued stock trading near record highs.
Company snapshot
- Company: Eli Lilly and Company · Ticker: LLY (NYSE)
- Sector: Healthcare · Pharmaceuticals · a Dow 30 component
- Founded: 1876, Indianapolis, Indiana — still headquartered there today
- What it makes: Prescription medicines across diabetes, obesity, oncology, immunology and neuroscience
- The franchise: Tirzepatide, sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management)
- Also: Verzenio (oncology), Taltz and Omvoh (immunology), Jaypirca, plus a deep late-stage pipeline
- Scale: Sells in roughly 125 markets; more than 50,000 employees; first healthcare company to a $1T market cap (Nov 2025)
Snapshot items are widely reported company facts; the Q2 results are sourced below.
What actually happened
Lilly delivered a record, broad-based beat. Revenue came in around $23.0 billion — up roughly 48% year over year and well ahead of the roughly $20.7 billion analysts expected. Non-GAAP earnings of $8.38 per share rose 33% from a year ago and landed about $2.37 above consensus, a large margin for a company this size. Growth was led by volume: more patients starting and staying on Lilly’s newest medicines.
On the strength of the quarter, Lilly raised its full-year 2026 revenue guidance to a range of $85 billion to $87 billion, up from a prior $82 billion to $85 billion. A guidance raise of that size, this deep into the year, signals management sees the demand trend continuing rather than cooling. The market read it that way, sending shares up about 6% in pre-market trading toward record territory.
The numbers that moved it
| Metric | Q2 2026 | Context |
|---|---|---|
| Revenue | ~$23.0B (record) | +~48% YoY, beat ~$20.7B est. |
| Adjusted EPS | $8.38 | +33% YoY; ~$2.37 above est. (~$6.01) |
| Mounjaro revenue | $9.94B | +91% YoY (type 2 diabetes) |
| Zepbound revenue | $4.93B | +46% YoY (weight management) |
| FY26 revenue guidance | $85–87B | raised from $82–85B |
| Stock reaction | ~+6% | to ~$1,184 pre-market |
Sources: Eli Lilly Q2 2026 release (investor.lilly.com), CNBC, RTTNews. Figures as reported.
The two figures that matter most are Mounjaro at nearly $10 billion, up about 91%, and Zepbound at almost $5 billion, up 46%. Together, a single molecule — tirzepatide — is now generating close to $15 billion in a single quarter. Few products in the history of the industry have scaled like this, and the raised guidance says Lilly expects the ramp to keep going.
Six months of tape
Lilly has spent the past two years as one of the market’s defining large-caps, precisely because it sits at the center of the biggest new drug category in a generation. A record quarter with a doubling of its diabetes flagship is the kind of print that pushes an already-expensive stock to new highs — while also, fairly, raising the bar for what it has to deliver next.
Inside the business: how Eli Lilly makes money
Lilly sells prescription medicines across several therapeutic areas, but the story right now is concentrated in metabolic health. Tirzepatide is a single molecule marketed under two brands: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Both work on the GLP-1 (and GIP) pathways that curb appetite and improve blood-sugar control, and both are in the steep part of their growth curves as manufacturing capacity expands and access broadens.
Beyond the franchise, Lilly runs a genuinely diversified book: Verzenio in oncology, Taltz and Omvoh in immunology, Jaypirca in blood cancers, and a long list of legacy diabetes and neuroscience products. It is also investing heavily to build the next leg of growth, including an oral weight-loss and diabetes program that could widen the market well beyond injectables. That diversification is why a beat this quarter came from volume across the portfolio, not a single line item.
The company has committed billions of dollars to new manufacturing plants, much of it in Indiana, specifically to make more tirzepatide. In a market where demand has repeatedly outrun supply, the ability to actually produce the drug is itself a competitive moat — and a big reason the guidance raise is credible.
Why this quarter matters
Three things stand out. First, the scale: growing revenue roughly 48% when you are already the largest company in your industry is extraordinary and shows the obesity and diabetes wave is still early. Second, the quality of the beat — it came from patient volume, not accounting or one-time items, which tends to be more durable. Third, the guidance raise reframes 2026 from “great year” to “even better than we thought,” and management rarely lifts a full-year outlook mid-stream unless the underlying trend is firmly in place. The combination is why the stock pushed to new highs on the print.
Keeping it real
One honest note, because it matters: LLY is not a cheap stock. It trades near record highs at a premium valuation, which means a great deal of good news is already priced in, and richly valued names can be unforgiving if growth so much as decelerates. Competition in weight-loss is intensifying, with a well-funded rival and a wave of next-generation and oral entrants all chasing the same market. And even in this blockbuster quarter, net prices on some products slipped as volumes surged — a reminder that pricing, rebates and eventual insurance and policy pressure are real forces on the business. None of that undoes a genuinely record quarter; it just means Lilly is a high-quality company carrying high expectations.
What to watch next
From here, the signals to track are concrete: whether tirzepatide volumes keep climbing as capacity comes online, how Lilly’s oral programs progress through late-stage trials, how pricing and gross-to-net trends hold up as access broadens, and how the company defends share against intensifying competition. Because Lilly now sells the defining medicines of the obesity era, its quarterly results double as a real-world gauge of that entire market — and right now, that gauge is at a record.
The bottom line
Eli Lilly booked a record ~$23 billion quarter, beat earnings by more than $2 a share, raised its full-year outlook, and watched its two flagship drugs grow 91% and 46% — a standout result powered by the biggest new category in medicine. It is a 149-year-old institution that has become the single most important company in obesity and diabetes, and this quarter proved the demand is still building. It carries real valuation and competitive risk and trades at record highs, so it is a high-expectations name — but a quarter like this is exactly why investors keep betting on Lilly.
Get the next Top Stock Pick in your inbox — free.
Recent Top Stock Picks
- Caterpillar Just Booked Its First $20 Billion Quarter — and Data Centers Are Fueling It
- Atkore Is Getting Bought for $3.8 Billion — Shareholders Just Won a 30% Premium
- Fortinet’s Billings Just Jumped 33% — Cybersecurity Demand Is Accelerating, Not Slowing
- Microsoft’s Azure Just Crossed $100 Billion — the Clearest Sign Yet of Who’s Winning AI
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. TopStockPicks.co is not a registered investment advisor and is not a broker-dealer. TopStockPicks.co has NOT BEEN COMPENSATED for coverage of LLY. TopStockPicks.co and its affiliates or officers may buy and sell shares of LLY in the open market at any time without notice. TopStockPicks.co does not set price targets on securities. Always do your own due diligence and consult your financial advisor. Never invest into a stock discussed by TopStockPicks.co unless you can afford to lose your entire investment.
